{
    "clinical_study": {
        "@rank": "66950", 
        "arm_group": {
            "arm_group_label": "Travoprost", 
            "arm_group_type": "Experimental", 
            "description": "Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (\u00b1 60 minutes) for 7 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and describe the steadystate plasma\n      pharmacokinetic profiles of Travoprost ophthalmic solution, 0.004% (new formulation)\n      following a once daily administration for 7 days in pediatric glaucoma or ocular\n      hypertension patients."
        }, 
        "brief_title": "Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Less than 18 years of age at the time of screening.\n\n          -  Diagnosis of glaucoma or ocular hypertension in at least 1 eye.\n\n          -  Parent/legal guardian must provide informed consent, and children must agree to sign\n             an approved assent form when applicable.\n\n          -  Must agree to comply with the requirements of the study and must be accompanied by a\n             parent/guardian.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Females of childbearing potential that are currently pregnant, have a positive result\n             on a pregnancy test at the Screening Visit, intend to become pregnant during the\n             study period, are breast feeding, or are not using birth control measures.\n\n          -  1 sighted eye or monocular, including patients who cannot be dosed in both eyes for\n             any reason.\n\n          -  History of chronic, recurrent or severe inflammatory eye disease.\n\n          -  Ocular trauma requiring medical attention within the past 3 months prior to the\n             Screening Visit.\n\n          -  Ocular infection or ocular inflammation within the past 30 days prior to the\n             Screening Visit.\n\n          -  Clinically significant or progressive retinal disease such as retinal degeneration,\n             diabetic retinopathy, or retinal detachment.\n\n          -  Other severe ocular pathology (including severe dry eye), that in the opinion of the\n             Investigator, would preclude the administration of a topical prostaglandin analogue.\n\n          -  Intraocular surgery within the past 30 days prior to the Screening Visit.\n\n          -  Any abnormality preventing reliable tonometry.\n\n          -  Any other conditions including severe illness which would make the patient, in the\n             opinion of the Investigator, unsuitable for the study.\n\n          -  Hypersensitivity to prostaglandin analogues or to any component of the study\n             medications in the opinion of the Investigator.\n\n          -  Therapy with another investigational agent or device within 30 days prior to the\n             Screening Visit.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658839", 
            "org_study_id": "C-12-009", 
            "secondary_id": "2012-001640-22"
        }, 
        "intervention": {
            "arm_group_label": "Travoprost", 
            "description": "Travoprost ophthalmic solution, 0.004%, new formulation", 
            "intervention_name": "Travoprost ophthalmic solution, 0.004% (new formulation)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Travoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pediatric glaucoma", 
            "pediatric ocular hypertension", 
            "travoprost"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center at 1-888-451-3937 for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed analyte plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }, 
            {
                "measure": "Time to reach Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }, 
            {
                "measure": "Time to last measurable concentration (Tlast)", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }, 
            {
                "measure": "Area under the analyte plasma concentration-time curve to the last quantifiable sampling time point [AUC(0-last)]", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }, 
            {
                "measure": "Area under the analyte plasma concentration-time curve over the dosing interval (inf)[AUC(0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }, 
            {
                "measure": "Half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Day 7: predose, 0, 10, 20, 40, 80 minutes post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}